Inclusion Criteria:

          -  Histologically or cytologically confirmed, immunotherapy naïve or PD-1/PD-L1
             pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to
             curative treatment. Subjects may be treatment naive or could have received one prior
             platinum based chemotherapy for non-small cell lung cancer and subjects with a
             documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the
             appropriate therapy and progressed

          -  Histologically or cytologically confirmed unresectable or metastatic melanoma that had
             confirmed progressive disease during treatment with anti-PD-1/PD-L1 therapy. Subjects
             with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK
             inhibitor regimen prior to anti-PD-1/PD-L1 therapy.

          -  Measurable disease by RECIST 1.1

          -  ECOG performance status of 0 or 1

          -  Adequate bone marrow, liver and kidney function

          -  Negative pregnancy test for women of child bearing potential

          -  Agreement to use effective methods of contraception per the protocol requirements

        Exclusion Criteria:

          -  Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1,
             anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents in the subsets of
             patients that must have previous treatment with anti-PD-1/PD-L1 therapy

          -  Second malignancy (solid or hematologic) within the past 3 years except locally
             curable cancers that have been apparently cured

          -  Active, known, clinically serious infections within the 14 days prior to first dose of
             investigational product

          -  Use of systemic corticosteroids or other systemic immunosuppressive drugs

          -  Active, known or suspected autoimmune disease

          -  History of (non-infectious) pneumonitis that required corticosteroids or current
             pneumonitis

          -  History of interstitial lung disease

          -  History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for
             subjects with metastatic melanoma or NSCLC.